Abstract
Introduction The role of some biomarkers such as S100 beta (S100B) has been somewhat known in
determining the severity of primary acute spinal cord injury (SCI), and today, it
has been the basis of various relevant studies. Therefore, this study estimates the
S100B level in serum and cerebrospinal fluid (CSF) in patients with spinal injuries.
Methods This was a descriptive-analytic study. In this study, 31 patients with acute SCI
referred to Sari Imam Khomeini Hospital, Iran, were recruited. Patients were divided
into two groups of complete and incomplete SCI according to the American Spinal Injury
Association (ASIA). The S100B concentrations in serum and CSF levels were compared
between the two groups.
Result There was only significant positive correlation between S100B CSF concentration and
complete SCI based on the ASIA criterion, meaning that in cases of complete SCI the
S100B CSF concentration was significantly increased correlation coefficient (CC) (cc = 0.529
and p = 0.002). Based on the results of serum S100B protein concentration, 14.70 ng/dL
with a sensitivity of 66.7% and specificity of 55% was determined as cutoff for complete
SCI. Also, about the CSF S100B protein level variable, concentration of 342.18 ng/dL
with 100% sensitivity and 64% specificity was determined as cutoff for complete injury.
Conclusion The results of this unique study have shown that S100B were useful markers for predicting
the prognosis of patients with acute SCI and cutoff points determined for serum and
especially CSF concentrations can differentiate complete and incomplete SCI.
Keywords
cerebrospinal fluid - S100 beta protein - spinal cord injury
